BioCentury | Aug 31, 2017
Translation in Brief

Extinguishing aversion

Last month in the Journal of Neuroscience , a team from the Chinese Academy of Sciences showed activating RAC1 could help treat opioid addiction by extinguishing the aversive memories of withdrawal that cause relapse in some...
BioCentury | Jul 21, 2016
Distillery Therapeutics

Therapeutics: Cytoskeleton associated protein 4 (CKAP4); dickkopf homolog 1 (DKK1)

...suggest inhibiting CKAP4 could help treat DKK1-expressing lung and pancreatic cancers. In patients, DKK1 and CKAP4...
...expression was higher in tumors than in surrounding normal tissue, and combined high DKK1 and CKAP4...
...tumor growth compared with control antibody. Next steps include identifying testing an anti-CKAP4 antibody. TARGET/MARKER/PATHWAY: Cytoskeleton associated protein 4 (CKAP4)...
BioCentury | Nov 10, 2011
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Activity-regulated cytoskeleton associated protein (ARC) Studies in mice suggest antagonizing ARC could help treat AD. In mouse brain slices, Arc interacted with...
BioCentury | Oct 31, 2005

Ebb & Flow

Cerimon's $70 million series A round probably turned some heads last week, as the company's lone products are topical formulations of diclofenac, an NSAID that's rather long of tooth. However, the company's directors and investors...
Items per page:
1 - 4 of 4